Inhibition of CD40-mediated endothelial cell activation with antisense oligonucleotides

Area of Science:

• Immunology
• Molecular Biology

Background:

• CD40-CD154 interactions are crucial for immune response amplification and are a target for immune intervention.
• Previous work showed human CD154 binding to porcine CD40 up-regulates VCAM-1 and MHC class II on PAECs, inhibitable by a monoclonal antibody (mAb).
• This study investigates antisense oligonucleotides (ASOs) as an alternative to mAbs for blocking the CD40-CD154 pathway.

Purpose of the Study:

• To explore antisense oligonucleotides (ASOs) as a novel method to inhibit CD40-CD154 interactions.
• To assess the potency and specificity of ASOs targeting porcine CD40.

Main Methods:

• Ten ASOs were designed based on the porcine CD40 cDNA sequence.
• ASOs were tested for their ability to reduce CD40 expression and subsequent CD40-mediated PAEC activation.
• Ribonuclease protection assays were used to detect mRNA cleavage products.

Main Results:

• Four ASOs significantly reduced porcine CD40 surface expression on PAECs within 48 hours.
• Eight ASOs induced mRNA cleavage, indicating target engagement.
• One ASO (ASO-9) demonstrated potent inhibition of PAEC activation (IC50 ~1 nM), comparable to a blocking mAb.
• ASO specificity was confirmed by observing no effect on tumor necrosis factor alpha receptor signaling.

Conclusions:

• ASOs can potently and specifically inhibit CD40-dependent activation pathways.
• ASOs represent a promising alternative therapeutic strategy to monoclonal antibodies for immune modulation.